Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common stock, $0.0001 par value per share
-
Shares outstanding
-
75.9M
-
Number of holders
-
120
-
Total shares
-
52.2M
-
Shares change
-
+7.29M
-
Total reported value, excl. options
-
$1.96B
-
Value change
-
+$277M
-
Put/Call ratio
-
0.95
-
Number of buys
-
83
-
Number of sells
-
-34
-
Price
-
$37.73
Significant Holders of CG Oncology, Inc. - Common stock, $0.0001 par value per share (CGON) as of Q3 2024
filings reported holding CGON - CG Oncology, Inc. - Common stock, $0.0001 par value per share as of Q3 2024.
CG Oncology, Inc. - Common stock, $0.0001 par value per share (CGON) has 120 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.2M shares
of 75.9M outstanding shares and own 68.79% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (5.48M shares), VANGUARD GROUP INC (5.08M shares), TCG Crossover Management, LLC (3.67M shares), BlackRock, Inc. (3.57M shares), BRAIDWELL LP (3.17M shares), Kynam Capital Management, LP (1.77M shares), STATE STREET CORP (1.7M shares), Avidity Partners Management LP (1.66M shares), JANUS HENDERSON GROUP PLC (1.53M shares), and RA CAPITAL MANAGEMENT, L.P. (1.4M shares).
This table shows the top 120 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.